PATENTSCOPE sera indisponible quelques heures pour des raisons de maintenance le mardi 19.11.2019 à 16:00 CET
Recherche dans les collections de brevets nationales et internationales
Certains contenus de cette application ne sont pas disponibles pour le moment.
Si cette situation persiste, veuillez nous contacter àObservations et contact
1. (WO1995035300) PURINE, INDOL ET PYRIMIDINE DE (DIHYDROXYBORYL)ALKYLE A SUBSTITUTION EN N, UTILES COMME INHIBITEURS DE CYTOKINES INFLAMMATOIRES
Note: Texte fondé sur des processus automatiques de reconnaissance optique de caractères. Seule la version PDF a une valeur juridique

WHAT IS CLAIMED IS:

1. A compound of the formula


wherein R1 and R2 are both hydrogen atoms, or together are a propylene chain bridging the two oxygen atoms;
n is 2-6; and
P is a purine, indole or pyrimidine base residue bonded via the N9 in the case of a purine base or via the N1 in the case of an indole or pyrimidine base; and the
pharmaceutically acceptable salts thereof.

2. The compound according to Claim 1 wherein R1 and R2 are both hydrogen.

3. The compound according to Claim 2 wherein n is 4.

4. The compound according Claim 3 wherein the
pyrimidine base residue is derived from thymine.

5. The compound according to Claim 3 wherein the purine base residue is derived from guanine.

6. The compound according to Claim 3 wherein the purine base residue is derived from hypoxanthine.

7. The compound according to Claim 3 wherein the purine base residue is derived from 6-chloropurine.

8. The compound according to Claim 3 wherein the purine base residue is derived from 2-amino-6-chloropurine.

9. A pharmaceutical composition which comprises a therapeutically effective amount of a compound of the formula



wherein both R1 and R2 are both hydrogen atoms, or together are a propylene chain bridging the two oxygen atoms; n is 2-6; and P is a purine, indole or pyrimidine base residue bonded via the N9 in the case of a purine base or via the N1 in the case of an indole or pyrimidine base; and a carrier therefor.

10. The composition according to Claim 9 wherein R1 and R2 are both hydrogen.

11. The composition according to Claim 10 wherein n is 4.

12. The composition according Claim 11 wherein the pyrimidine base residue is derived from thymine.

13. The composition according to Claim 11 wherein the purine base residue is derived from guanine.

14. The composition according to Claim 11 wherein the purine base residue is derived from hypoxanthine.

15. The composition according to Claim 11 wherein the purine base residue is derived from 6-chloropurine.

16. The composition according to Claim 11 wherein the purine base residue is derived from 2-amino-6-chloropurine.

17. A method of inhibiting inflammatory cytokines in a mammal in need of such treatment which comprises
administration of a therapeutically effective amount of a compound of the formula


wherein R1 and R2 are both hydrogen atoms, or together are a propylene chain bridging the two oxygen atoms;
n is 2-6; and
P is a purine, indole or pyrimidine base residue bonded via the N9 in the case of a purine base or via the N1 in the case of an indole or pyrimidine base; and the
pharmaceutically acceptable salts thereof.

18. The method according to Claim 17 wherein R1 and R2 are both hydrogen.

19. The method according to Claim 18 wherein n is 4.

20. The method according Claim 19 wherein the pyrimidine base residue is derived from thymine.

21. The method according to Claim 19 wherein the purine base residue is derived from guanine.

22. The method according to Claim 19 wherein the purine base residue is derived from hypoxanthine.

23. The method according to Claim 19 wherein the purine base residue is derived from 6-chloropurine.

24. The method according to Claim 19 wherein the purine base residue is derived from 2-amino-6-chloropurine.

25. A method according to Claim 17 wherein the mammal under treatment is afflicted with septic shock.

26. The method according to Claim 17 wherein the mammal under treatment is afflicted with cachexia.

27. The method according to Claim 17 wherein the mammal under treatment is afflicted with rheumatoid arthritis.

28. The method according to Claim 17 wherein the mammal under treatment is afflicted with inflammatory bowel disease.

29. The method according to Claim 17 wherein the mammal under treatment is afflicted with multiple sclerosis.

30. The method according to Claim 17 wherein the mammal under treatment is afflicted with AIDS.

31. The method according to Claim 17 wherein the mammal under treatment is afflicted with Alzheimer's Disease.

32. The method according to Claim 17 wherein the inflammatory cytokine being inhibited is tumor necrosis factor (TNF).

33. The method according to Claim 32 wherein the mammal under treatment is afflicted with septic shock.

34. The method according to Claim 32 wherein the mammal under treatment is afflicted with cachexia.

35. The method according to Claim 32 wherein the mammal under treatment is afflicted with rheumatoid arthritis.

36. The method according to Claim 32 wherein the mammal under treatment is afflicted with inflammatory bowel disease.

37. The method according to Claim 32 wherein the mammal under treatment is afflicted with multiple sclerosis.

38. The method according to Claim 32 wherein the mammal under treatment is afflicted with AIDS.

39. The method according to Claim 32 wherein the mammal under treatment is afflicted with Alzheimer's Disease.